ROTOP receives marketing authorisation for its diagnostic product RoTecPSMA® in the United Kingdom.

We are delighted that the new product RoTecPSMA® from our portfolio company ROTOP has received marketing authorisation in the UK.

RoTecPSMA® is a diagnostic kit that uses technetium-99m and has been specially developed for SPECT imaging in prostate cancer patients. It is the first PSMA SPECT tracer to be approved in a European country. It closes an important gap in care and makes advanced diagnostics more accessible for prostate cancer patients. Access to PSMA imaging is a key prerequisite for PSMA radioligand therapy yet remains severely limited in many countries.

Read the full article here.